- Home
- DAWN vs KIND Comparison
DAWN vs KIND Comparison
Compare DAWN & KIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- KIND
- Stock Information
- Founded
- DAWN 2018
- KIND 2011
- Country
- DAWN United States
- KIND United States
- Employees
- DAWN N/A
- KIND N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- KIND Computer Software: Programming Data Processing
- Sector
- DAWN Health Care
- KIND Technology
- Exchange
- DAWN Nasdaq
- KIND Nasdaq
- Market Cap
- DAWN 658.9M
- KIND 608.3M
- IPO Year
- DAWN 2021
- KIND N/A
- Fundamental
- Price
- DAWN $7.02
- KIND $1.66
- Analyst Decision
- DAWN Strong Buy
- KIND Buy
- Analyst Count
- DAWN 7
- KIND 4
- Target Price
- DAWN $31.57
- KIND $2.56
- AVG Volume (30 Days)
- DAWN 1.3M
- KIND 2.1M
- Earning Date
- DAWN 07-29-2025
- KIND 08-07-2025
- Dividend Yield
- DAWN N/A
- KIND N/A
- EPS Growth
- DAWN N/A
- KIND N/A
- EPS
- DAWN N/A
- KIND N/A
- Revenue
- DAWN $161,922,000.00
- KIND $248,306,000.00
- Revenue This Year
- DAWN $17.98
- KIND $1.66
- Revenue Next Year
- DAWN $49.50
- KIND $10.87
- P/E Ratio
- DAWN N/A
- KIND N/A
- Revenue Growth
- DAWN N/A
- KIND 12.01
- 52 Week Low
- DAWN $6.08
- KIND $1.32
- 52 Week High
- DAWN $16.76
- KIND $3.00
- Technical
- Relative Strength Index (RSI)
- DAWN 58.34
- KIND 55.55
- Support Level
- DAWN $6.52
- KIND $1.55
- Resistance Level
- DAWN $7.24
- KIND $1.73
- Average True Range (ATR)
- DAWN 0.26
- KIND 0.06
- MACD
- DAWN 0.07
- KIND 0.01
- Stochastic Oscillator
- DAWN 78.37
- KIND 64.04
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services. It offers a comprehensive suite of advertising solutions designed to deliver exceptional value for businesses of all size.